title: Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.
abstract: We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor.
authors.affiliation: Department of Hematology, Toranomon Hospital, Toranomon, Tokyo, Japan.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yuji
authors.forename: Shigesaburo
authors.initials: S
authors.lastname: Miyakoshi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kato
authors.forename: Yuji
authors.initials: Y
authors.lastname: Miura
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Myojo
authors.forename: Naoko
authors.initials: N
authors.lastname: Murashige
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Kishi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Eiji
authors.initials: E
authors.lastname: Kusumi
authors.forename: Hiroto
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Tamae
authors.initials: T
authors.lastname: Hamaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Matsumura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
authors.forename: Shigeru
authors.initials: S
authors.lastname: Masuo
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Masuoka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Wake
authors.forename: Junichi
authors.initials: J
authors.lastname: Ueyama
authors.forename: Akiko
authors.initials: A
authors.lastname: Yoneyama
authors.forename: Ko
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Haruhisa
authors.initials: H
authors.lastname: Nagoshi
authors.forename: Michio
authors.initials: M
authors.lastname: Matsuzaki
authors.forename: Shinichi
authors.initials: S
authors.lastname: Morinaga
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Muto
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Takeue
authors.forename: Shuichi
authors.initials: S
authors.lastname: Taniguchi
mesh_terms: D000328:Adult; D000368:Aged; D036101:Cord Blood Stem Cell Transplantation; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019172:Transplantation Conditioning / Q000379:methods; D014916:Whole-Body Irradiation